文章摘要
王晶 ,江秀丽 ,雷小晶 ,李加梅 ,郑加平.益生菌制剂联合盐酸多奈哌齐治疗轻、中度阿尔茨海默病的研究[J].神经损伤功能重建,2022,17(7):378-383
益生菌制剂联合盐酸多奈哌齐治疗轻、中度阿尔茨海默病的研究
Efficacy Analysis of Donepezil Combined with Probiotics in Treatment of Mild and ModerateAlzheimer's Disease
  
DOI:
中文关键词: 阿尔茨海默病  益生菌  盐酸多奈哌齐片  认知功能  肠道菌群  炎症因子
英文关键词: Alzheimer's disease  probiotics  donepezil hydrochloride  cognitive function  intestinal flora  inflammatory cytokines
基金项目:
作者单位
王晶1 ,江秀丽2 ,雷小晶1 ,李加梅2 ,郑加平2 1. 潍坊医学院神经 病学专业 2. 日照市人民医院 神经内科 
摘要点击次数: 1627
全文下载次数: 1713
中文摘要:
      目的:探讨益生菌制剂联合盐酸多奈哌齐治疗轻中度阿尔茨海默病的疗效。方法:AD患者66例,随 机分为联合组(给予多奈哌齐片+双歧杆菌三联活菌胶囊)及对照组(多奈哌齐片+淀粉胶囊),治疗12 周后 评估疗效,包括:认知功能评分、炎症因子、肠道菌群及不良反应发生情况。结果:治疗后,2 组的简易智力 状态检查量表(MMSE)评分、日常生活能力量表(ADL)评分均较治疗前改善(P<0.05),且联合组的MMSE 评分较对照组升高(P<0.05),但ADL评分差异无统计学意义。治疗后,2组血清IL-1β、CRP、IL-6、TNF-α 水平均较治疗前显著降低(P<0.05),且在联合组中 IL-1β、IL-6 及 TNF-α水平下降程度较对照组更明显 (P<0.05),CRP差异无统计学意义(P>0. 05)。肠道菌群组间物种分布比较显示:门水平上厚壁菌门、拟杆 菌门、变形菌门和放线菌门为各组优势菌门,经治疗后,联合组中厚壁菌门丰度较对照组显著增多(P< 0.05)。治疗后在属水平上,对照组较治疗前梭菌属显著减少(P<0.05);联合组中布劳特氏菌属和伯克霍 尔德氏属较治疗前明显减少(P<0.05),而罗氏菌属、乳杆菌属显著增加(P<0.05),双歧杆菌属也略有增 加。治疗后与对照组比较,乳杆菌属、梭菌属、粪球菌属、瘤胃球菌属、巨单胞菌属、萨特氏菌属等丰度在联 合组中偏高(P<0.05)。炎症因子与罗斯氏菌属、颤螺菌属、Anaerostipes等有益菌属呈负相关,与伯克霍尔 德氏菌属、苏黎世杆菌属等有害菌属呈正相关。肠道菌群组间多样性比较显示,α多样性及β多样性无改 变。结论:益生菌联合多奈哌齐治疗轻中度AD 患者进一步获益,且安全性好。
英文摘要:
      To explore efficacy of probiotics combined with donepezil in the treatment of mild and moderate Alzheimer's disease (AD). Methods: Sixty-six AD patients were randomly divided into group A (donepezil tablets + Bifidobacterium triple viable capsules) and group B (donepezil tablets + starch capsules). After 12 weeks of treatment, the efficacy was evaluated, including cognitive function score, inflammatory factors, intestinal flora, and incidence of adverse reactions. Results: After treatment, the mini-mental state examination (MMSE) score and activities of daily living (ADL) score of both groups improved compared with before treatment (P<0.05); the MMSE score of group A was significantly higher than that of group B (P<0.05), but the difference in ADL score was not statistically significant. After treatment, serum levels of inflammatory factors such as IL-1β, IL-6, TNF-α, and CRP were significantly lower in both groups than before treatment (P< 0.05), although the reduction in levels of IL-1β, IL-6, and TNF-α was more pronounced in group A than in group B (P<0.05); the difference in CRP between the groups was not statistically significant (P>0.05). Comparison of the distribution of bacterial species among the intestinal flora groups showed that at the portal level after treatment, Firmicutes, Bacteroides, Proteobacteria, and Actinomycetes were predominant in each group. After treatment, the abundance of Firmicutes was significantly higher in group A compared to group B (P<0.05). Clostridium in group B was significantly reduced compared with that before treatment (P<0.05). In group A, Blautia and Burkholderia were significantly decreased compared with before treatment (P<0.05), while Roseburia and Lactobacillus were significantly increased (P<0.05), and Bifidobacteria were also slightly increased. After treatment, the relative abundance of Lactobacillus, Clostridium, Coprococcus, Ruminococcus, Megomonas, and Suttelia was higher in group A (P<0.05). Correlation analysis found that the inflammatory factor was negatively correlated with butyric acid-producing bacteria such as Roseburia, Oscillospira, and Anaerostipes and positively correlated with harmful bacteria such as Burkholderia and Turicibacter. A comparison of intestinal flora group diversity showed no significant change in α diversity and β diversity. Conclusion: Probiotics combined with donepezil in the treatment of patients with mild to moderate AD offers enhanced benefits and good safety.
查看全文   查看/发表评论  下载PDF阅读器
关闭